Abstract:Parkinson's disease varies widely in clinical manifestations, course of progression and biomarker profiles from person to person. Identification of distinct Parkinson's disease subtypes is of great priority to illuminate underlying pathophysiology, predict progression and develop more efficient personalized care approaches. There is currently no clear way to define and divide subtypes in Parkinson's disease. Using data from the Parkinson's Progression Markers Initiative, we aimed to identify distinct subgroups via cluster analysis of a comprehensive dataset at baseline (i.e. cross-sectionally) consisting of clinical characteristics, neuroimaging, biospecimen and genetic information, then to develop criteria to assign patients to a Parkinson's disease subtype. Four hundred and twenty-one individuals with de novo early Parkinson's disease were included from this prospective longitudinal multicentre cohort. Hierarchical cluster analysis was performed using data on demographic and genetic information, motor symptoms and signs, neuropsychological testing and other non-motor manifestations. The key classifiers in cluster analysis were a motor summary score and three non-motor features (cognitive impairment, rapid eye movement sleep behaviour disorder and dysautonomia). We then defined three distinct subtypes of Parkinson's disease patients: 223 patients were classified as 'mild motor-predominant' (defined as composite motor and all three non-motor scores below the 75th percentile), 52 as 'diffuse malignant' (composite motor score plus either ≥1/3 non-motor score >75th percentile, or all three non-motor scores >75th percentile) and 146 as 'intermediate'. On biomarkers, people with diffuse malignant Parkinson's disease had the lowest level of cerebrospinal fluid amyloid-β (329.0 ± 96.7 pg/ml, P = 0.006) and amyloid-β/total-tau ratio (8.2 ± 3.0, P = 0.032). Data from deformation-based magnetic resonance imaging morphometry demonstrated a Parkinson's disease-specific brain network had more atrophy in the diffuse malignant subtype, with the mild motor-predominant subtype having the least atrophy. Although disease duration at initial visit and follow-up time were similar between subtypes, patients with diffuse malignant Parkinson's disease progressed faster in overall prognosis (global composite outcome), with greater decline in cognition and in dopamine functional neuroimaging after an average of 2.7 years. In conclusion, we introduce new clinical criteria for subtyping Parkinson's disease based on a comprehensive list of clinical manifestations and biomarkers. This clinical subtyping can now be applied to individual patients for use in clinical practice using baseline clinical information. Even though all participants had a recent diagnosis of Parkinson's disease, patients with the diffuse malignant subtype already demonstrated a more profound dopaminergic deficit, increased atrophy in Parkinson's disease brain networks, a more Alzheimer's disease-like cerebrospinal fluid profile and faster progression of motor and cognitive deficits.

Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.

The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients

Approaches to Early Parkinson's Disease Subtyping

Identification of Parkinson’s Disease PACE Subtypes and Repurposing Treatments Through Integrative Analyses of Multimodal Data

Data-driven subtyping of Parkinson's disease: comparison of current methodologies and application to the Bochum PNS cohort

The heterogeneity of Parkinson's disease

Two Distinct Trajectories of Clinical and Neurodegeneration Events in Parkinson’s Disease

Progression subtypes in Parkinson's disease identified by a data-driven multi cohort analysis

An Examination of Cognitive Heterogeneity in Parkinson Disease: The Dual-Syndrome Hypothesis

Parkinson's Disease Non-Motor Subtypes Classification in a Group of Slovenian Patients: Actuarial vs. Data-Driven Approach

Disease Progression of Data-Driven Subtypes of Parkinson's Disease: 5-Year Longitudinal Study from the Early Parkinson's disease Longitudinal Singapore (PALS) Cohort

Clinically relevant connectivity features define three subtypes of Parkinson's disease patients

MRI subtypes in Parkinson's disease across diverse populations and clustering approaches

Neuropsychological and Clinical Heterogeneity of Cognitive Impairment and Dementia in Patients with Parkinson's Disease

Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression

Consistency and Stability of Motor Subtype Classifications in Patients with De Novo Parkinson's Disease

Prediction of Cognitive Heterogeneity in Parkinson's Disease: A 4-Year Longitudinal Study Using Clinical, Neuroimaging, Biological and Electrophysiological Biomarkers

Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

Parkinson’s Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering

Elucidating Molecular Networks Underpinning Heterogeneity in Parkinson’s Disease Progression Across Clinical Manifestation Spectrum

The STRAT-PARK cohort: a personalized initiative to stratify Parkinson's disease